Skip to main content

Market Overview

Cantor Fitzgerald Initiates Coverage On Lineage Cell Therapeutics with Overweight Rating, Announces Price Target of $6


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for LCTX

Mar 2021Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2020Noble Capital MarketsInitiates Coverage OnOutperform

View More Analyst Ratings for LCTX
View the Latest Analyst Ratings


Related Articles (LCTX)

Posted-In: News Price Target Initiation Analyst Ratings

Latest Ratings

HBANRaymond JamesUpgrades
BWXTCredit SuisseDowngrades67.0
SAFEB. Riley SecuritiesInitiates Coverage On100.0
NOGPiper SandlerInitiates Coverage On22.0
ACNExane BNP ParibasUpgrades335.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at